To include your compound in the COVID-19 Resource Center, submit it here.

China and the U.S. are enacting policies that could stymie biomedical innovation

An overview of U.S. and China policies that could hurt both investment and innovaton in biotech

Amidst rising tensions between the U.S. and China, both governments have enacted policies in recent years that could hinder innovation and hurt public health over the long term.

Protectionist mindsets, coupled with concerns about industrial espionage and IP theft, have led both countries to erect barriers that will limit foreign access to their respective biopharma sectors.

Many of the policies mirror each other.

The escalation is not a

Read the full 667 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE